Richard Gray on a Longer Duration of Tamoxifen

Richard G. Gray, MA, MSc, a professor of medical statistics at the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Overall, Gray notes, fewer breast cancer recurrences were seen in the 10-year tamoxifen group than in the 5-year group. In all, women who continue tamoxifen treatment had a 25 percent lower recurrence rate and a 23 percent lower breast cancer mortality rate.

Read more about this study >>>

<<<

View more from the 2013 ASCO Annual Meeting